- Latest available (Revised)
- Original (As adopted by EU)
Commission Regulation (EU) No 1228/2014Show full title
Commission Regulation (EU) No 1228/2014 of 17 November 2014 authorising and refusing to authorise certain health claims made on foods and referring to the reduction of disease risk (Text with EEA relevance)
You are here:
- Regulations originating from the EU
- 2014 No. 1228
- Annexes only
What Version
More Resources
Legislation originating from the EU
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
This item of legislation originated from the EU
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
Status:
This is the original version as it was originally adopted in the EU.
This legislation may since have been updated - see the latest available (revised) version
ANNEX IPermitted health claims
| Application — Relevant provisions of Regulation (EC) No 1924/2006 | Applicant — Address | Nutrient, substance, food or food category | Claim | Conditions of use of the claim | Conditions and/or restrictions of use of the food and/or additional statement or warning | EFSA opinion reference |
|---|---|---|---|---|---|---|
| Article 14(1)(a) health claim referring to a reduction of a disease risk | Abtei Pharma Vertriebs GmbH, Abtei 1, 37696, Marienműnster, Germany. | Calcium | Calcium helps to reduce the loss of bone mineral in post-menopausal women. Low bone mineral density is a risk factor for osteoporotic bone fractures | The claim may be used only for food which provides at least 400 mg of calcium per quantified portion. Information shall be given to the consumer that the claim is specifically intended for women 50 years and older and the beneficial effect is obtained with a daily intake of at least 1 200 mg of calcium from all sources. | For foods with added calcium the claim may be used only for those targeting women 50 years and older | Q-2008-721 Q- 2009-00940 |
| Article 14(1)(a) health claim referring to a reduction of a disease risk | Abtei Pharma Vertriebs GmbH, Abtei 1, 37696, Marienműnster, Germany. | Calcium and vitamin D | Calcium and vitamin D help to reduce the loss of bone mineral in post-menopausal women. Low bone mineral density is a risk factor for osteoporotic bone fractures | The claim may be used only for food supplements which provide at least 400 mg of calcium and 15 μg of vitamin D per daily portion. Information shall be given to the consumer that the claim is specifically intended for women 50 years and older and the beneficial effect is obtained with a daily intake of at least 1 200 mg of calcium and 20 μg of vitamin D from all sources. | For food supplements with added calcium and vitamin D the claim may be used only for those targeting women 50 years and older | Q-2008-721 Q- 2009-00940 |
| Article 14(1)(a) health claim referring to a reduction of a disease risk | DSM Nutritional Products Europe AG, P.O. Box 2676, 4002 Basel, Switzerland. | Vitamin D | Vitamin D helps to reduce the risk of falling associated with postural instability and muscle weakness. Falling is a risk factor for bone fractures among men and women 60 years of age and older. | The claim may be used only for food supplements which provide at least 15 μg of vitamin D per daily portion. Information shall be given to the consumer that the beneficial effect is obtained with a daily intake of 20 μg of vitamin D from all sources. | For food supplements with added vitamin D the claim may be used only for those targeting men and women 60 years and older | Q-2010-01233 |
ANNEX IIRejected health claims
| Application — Relevant provisions of Regulation (EC) No 1924/2006 | Nutrient, substance, food or food category | Claim | EFSA opinion reference |
|---|---|---|---|
| Article 14(1)(a) health claim referring to a reduction of a disease risk | Glucosamine hydrocloride | Slowing down/reduce the destruction process of cartilage of the musculoskeletal system and consequently reduce the risk of osteoarthritis. | Q-2009-00412 |
| Article 14(1)(a) health claim referring to a reduction of a disease risk | Isolated soy protein | Protein-rich soybean component has been shown to lower/reduce blood cholesterol; blood cholesterol lowering may reduce the risk of (coronary) heart disease. | Q-2011-00784 |
| Article 14(1)(a) health claim referring to a reduction of a disease risk | Plant sterols in combination with Cholesternorm®mix | Actively lowers cholesterol. | Q-2009-00237 Q-2011-01114 |
| Article 14(1)(a) health claim referring to a reduction of a disease risk | Eicosapentanoic acid (EPA) | EPA has been shown to reduce the AA/EPA ratio in blood. A high AA/EPA level is a risk factor in the development of attention difficulties in children with ADHD-like symptoms. These children are also characterised by less hyperactivity and/or coexisting oppositional behaviour. | Q-2012-00573 |
| Article 14(1)(a) health claim referring to a reduction of a disease risk | Plant stanols (as plant stanol esters) | Consuming 2 g/day plant stanols (as plant stanol esters) as part of a diet low in saturated fat results in a 2-fold greater reduction in LDL-cholesterol than consuming a low saturated fat diet alone. High cholesterol is a risk factor in the development of coronary heart disease. | Q-2012-00915 |
Options/Help
Print Options
PrintThe Whole Regulation
PrintThe Annexes only
Legislation is available in different versions:
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Opening Options
Different options to open legislation in order to view more content on screen at once
More Resources
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as adopted version that was used for the EU Official Journal
- lists of changes made by and/or affecting this legislation item
- all formats of all associated documents
- correction slips
- links to related legislation and further information resources
More Resources
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as adopted version that was used for the print copy
- correction slips
Click 'View More' or select 'More Resources' tab for additional information including:
- lists of changes made by and/or affecting this legislation item
- confers power and blanket amendment details
- all formats of all associated documents
- links to related legislation and further information resources
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.